Rongli Wei - Publications

Corrigendum to "NEAT1/hsa-miR-372-3p axis participates in rapamycin-induced lipid metabolic disorder" [Free Radic. Biol. Med. 167 (2021) 1-11].

Journal: Free radical biology & medicine

Published: February 14, 2026

Integration of perioperative features and intragraft TCF7L2 expression to predict lipid metabolic disorder in liver transplant recipients.

Journal: Science China. Life sciences

Published: January 11, 2024

Transcription factor 7 like 2 promotes metastasis in hepatocellular carcinoma via NEDD9-mediated activation of AKT/mTOR signaling pathway.

Journal: Molecular medicine (Cambridge, Mass.)

Published: December 26, 2023

Establishment and validation of a cholesterol metabolism-related prognostic signature for hepatocellular carcinoma.

Journal: Computational and structural biotechnology journal

Published: June 28, 2022

E2F7 promotes mammalian target of rapamycin inhibitor resistance in hepatocellular carcinoma after liver transplantation.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: March 16, 2022

NEAT1/hsa-miR-372-3p axis participates in rapamycin-induced lipid metabolic disorder.

Journal: Free radical biology & medicine

Published: December 20, 2020

The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance.

Journal: Cell death & disease

Published: October 28, 2020

The circFASN/miR-33a pathway participates in tacrolimus-induced dysregulation of hepatic triglyceride homeostasis.

Journal: Signal transduction and targeted therapy

Published: August 25, 2019

USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation.

Journal: Gut

Published: August 08, 2019